The Personalisation of Glioblastoma Treatment Using Whole Exome Sequencing: A Pilot Study
Open Access
Abstract
The molecular heterogeneity of glioblastoma has been linked to differences in survival and treatment response, while the development of personalised treatments may be a novel way of combatting this disease. Here we show for the first time that low passage number cells derived from primary tumours are greater than an 86% match genetically to the tumour tissue. We used these cells to identify eight genes that could be used for the personalisation of glioblastoma treatment and discovered a number of personalised drug combinations that were significantly more effective at killing glioblastoma cells and reducing recurrence than the individual drugs as well as the control and non-personalised combinations. This pilot study demonstrates for the first time that whole exome sequencing has the potential be used to improve the treatment of glioblastoma patients by personalising treatment. This novel approach could potentially offer a new avenue for treatment for this terrible disease.Keywords
This publication has 59 references indexed in Scilit:
- Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugsJournal of Translational Medicine, 2014
- Loss of Atrx Sensitizes Cells to DNA Damaging Agents through p53-Mediated Death PathwaysPLOS ONE, 2012
- Somatic Mutations of PIK3R1 Promote GliomagenesisPLOS ONE, 2012
- Characterizing Mutational Heterogeneity in a Glioblastoma Patient with Double RecurrencePLOS ONE, 2012
- Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor responseProceedings of the National Academy of Sciences, 2012
- A Review of Three-Dimensional In Vitro Tissue Models for Drug Discovery and Transport StudiesJournal of Pharmaceutical Sciences, 2011
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- In vitro, high‐resolution 1H and 31P NMR based analysis of the lipid components in the tissue, serum, and CSF of the patients with primary brain tumors: one possible diagnostic viewNMR in Biomedicine, 2009
- Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor PathwayClinical Lung Cancer, 2009
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008